PCI Pharma closes acquisition of LSNE to expand CDMO services

Date: 2021-12-15   Author: Pankaj Singh  Category: #news

PCI Pharma closes acquisition of LSNE to expand CDMO services

PCI Pharma Services, a leading global CDMO (contract development and manufacturing organization) has reportedly announced the closure of the acquisition of LSNE (Lyophilization Services of New England) Inc., a Bedford-headquartered premier CDMO.

Under the acquisition, LSNE will bring five FDA-approved facilities to PCI in the United States (Wisconsin, New Hampshire), and Europe (Spain) with a sixth facility expecting to receive approval in the next year. The closure of this acquisition, along with capital promises for substantial expansion of capacity, will help create a centralized hub for its clients in the Northeast region.

This acquisition is a crucial step for PCI as LSNE will broaden its services as a global CDMO and build on its proficiency in specialty manufacturing, pharmaceutical packaging, and clinical trial supply.

PCI is now capable of providing integrated small and large molecule solutions for its commercial and clinical clients which includes global manufacturing capabilities in complicated formulations, high-potency, sterile fill-finish as well as lyophilization, which is a crucial manufacturing process generally used with biologic and injectable therapies.

Notably, this is PCI’s fourth acquisition in nearly three years, strengthening the company’s dedication to include new scale and capabilities to help its clients in introducing breakthrough therapies to patients across the world.

The high-growing segment of the injectable CDMO market is outpacing the overall market of pharma outsourcing and PCI is making huge investments like this acquisition in response to the ever-growing industrial landscape.

Founded in 1997, LSNE has a spectacular history of serving global biotechnology, pharmaceutical, and medical device companies. The company is distinguished by its expertise and ability to scale lyophilization as well as its high-quality capabilities of cGMP aseptic fill-finish.

For the record, PCI is a global CDMO that provides its clients with integrated drug development, packaging, and manufacturing capabilities that increase the speed to market of the products and opportunities for commercial success.

Source credit:

https://www.businesswire.com/news/home/20211213005053/en/PCI-Pharma-Services-Announces-the-Closing-of-Its-Acquisition-of-LSNE



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

Genetic Testing Market by Type, Application, Element - Global Trends and Forecast to 2027

Author: Rahul Varpe

Global market insights declares the publication of its latest research report, with the title ‘global Genetic Testing market’. This report sheds light on the analysis of the industry challenges, growth...


Dental CAD/CAM Market, Share, Growth, Trends and Forecast to 2027: Global Market Insights

Author: Rahul Varpe

Global market insights declares the publication of its latest research report, with the title ‘global Dental CAD/CAM Drugs market’. This report sheds light on the analysis of the industry challenges, g...


Companion Animal Drugs Market Research Report Analysis and Forecasts to 2027

Author: Rahul Varpe

Global market insights declares the publication of its latest research report, with the title ‘global Companion Animal Drugs market’. This report sheds light on the analysis of the industry challe...